SCHEMBL730244

SCHEMBL730244

COC(=O)c1cc(C)c(O)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.50
CA1 P00915 6/20 0.50
CA2 P00918 6/20 0.50
CA7 P43166 6/20 0.50
CA9 Q16790 6/20 0.50
CA14 Q9ULX7 6/20 0.50
PDK2 Q15119 1/20 0.50
PDK4 Q16654 1/20 0.50
CYP3A4 P08684 3/20 0.48
ACHE P22303 1/20 0.48
LMNA P02545 3/20 0.48
TSHR P16473 1/20 0.48
GAA P10253 4/20 0.47
XDH P47989 2/20 0.47
HPGD P15428 4/20 0.46
KDM4E B2RXH2 4/20 0.45
POLB P06746 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
NFKB1 P19838 1/20 0.45
GFER P55789 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2318133 0.92 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL20366958 0.89 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL2430255 0.89 KDM4E (0.50) CA12CA1CA2CA7CA9
SCHEMBL4906052 0.88 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL9128543 0.88 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL27902660 0.88 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL8980551 0.85 CA12 (0.57) CA12CA1CA2CA7CA9
SCHEMBL3198146 0.85 KDM4E (0.47) CA12CA1CA2CA7CA9
SCHEMBL3207481 0.85 MAPT (0.47) CA12CA1CA2CA7CA9
SCHEMBL27501597 0.84 KDM4E (0.59) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN claimed
US-12421452-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2025-09-23 US disclosed
CN-113748021-B Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2024-07-05 CN disclosed
US-20240084196-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-03-14 US disclosed
US-11884864-B2 Method for producing liquid-crystal polyester processed product HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2024-01-30 US disclosed
US-20220204853-A1 METHOD FOR PRODUCING LIQUID-CRYSTAL POLYESTER PROCESSED PRODUCT HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) 2022-06-30 US disclosed
CN-113748021-A Method for producing liquid crystal polyester processed product 本州化学工业株式会社 2021-12-03 CN disclosed
US-8729095-B2 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-20 US disclosed
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 US disclosed
US-8629271-B2 Compounds ASTRAZENECA AB (GB) 2014-01-14 US disclosed
US-7423185-B2 Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-09-09 US disclosed
EP-1593666-B1 AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF KISSEI PHARMACEUTICAL (JP) 2008-07-02 EP disclosed
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-04 US disclosed
US-20060128807-A1 Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-06-15 US disclosed
EP-1666473-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed
EP-1593666-A1 AMINO ALCOHOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2005-11-09 EP disclosed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient GPR17, CYSLTR1, KIT CA12 1542/4885CA1 542/4885CA2 374/4885
US-20060128807-A1 Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof ADRB3, ADRA2C, ADRA1A CA12 2510/4885CA1 2886/4885CA2 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.